Inhibitors of the epidermal growth factor receptor (EGFR) are a prototypic example and have produced consistently high response rates in a subgroup of patients with non–small-cell lung cancer (NSCLC) with activating EGFR mutations [1, 2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.